Apollomics APLM
NASDAQ APLM
$23.86 -1.02 (-4.04%)
As of: Sep 10, 2026 · 11:04 AM EDT

Apollomics (APLM) Non-Current Assets (2021 - 2025)

Apollomics' (APLM) quarterly Non-Current Assets came in at $663000.0 in Q4 2025, down 76.58% year-over-year from $2.8 million in Q4 2024, and down 33.03% quarter-over-quarter from $990000.0 in Q2 2025.

Analysis

Apollomics (APLM) Non-Current Assets (2021 - 2025) Analysis & Trends

Apollomics (APLM) has reported Non-Current Assets for 5 consecutive years, with $663000.0 the latest figure, recorded in Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 76.58% year-over-year to $663000.0 in Q4 2025; TTM through Dec 2025 was $663000.0, a 76.58% decrease from a year earlier, with the FY2025 full-year figure at $663000.0, down 76.58% from the prior year.
  • Non-Current Assets was $663000.0 for Q4 2025 at Apollomics, down from $990000.0 in the prior quarter.
  • Over five years, Non-Current Assets peaked at $24.1 million in Q4 2021 and troughed at $663000.0 in Q4 2025.
  • A 5-year average of $10.9 million and a median of $10.8 million in 2023 frame the typical range for Non-Current Assets.
  • Across the five-year window, Non-Current Assets retreated 14.06% in 2022 and plunged 83.93% in 2025, its largest moves.
  • Over 5 years, Non-Current Assets stood at $24.1 million in 2021, then declined by 14.06% to $20.7 million in 2022, then declined by 25.25% to $15.5 million in 2023, then plunged by 81.69% to $2.8 million in 2024, then sank by 76.58% to $663000.0 in 2025.
  • The last three Non-Current Assets figures came in at $663000.0 (Q4 2025), $990000.0 (Q2 2025), and $2.8 million (Q4 2024), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 60.68 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 35.42 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn 14.88 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 23.28 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn 1.96 Bn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn 5.15 Bn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 938.60 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 24.78 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn 564.41 Mn
10 Apollomics 34.50 Mn 31.23 Mn - 663,000.00
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 663,000.00
Jun 30, 2025 990,000.00
Dec 31, 2024 2.83 Mn
Jun 30, 2024 6.16 Mn
Dec 31, 2023 15.46 Mn
Jun 30, 2023 16.00 Mn
Dec 31, 2022 20.69 Mn
Dec 31, 2021 24.07 Mn